8-K: agilon health Q3 2025: Risk Adjustment Hits Revenue

agilon health reports third-quarter 2025 results, revealing a $73 million impact from lower-than-expected risk adjustment revenue and re-establishes its full-year outlook.

Summary

• Total revenue for the third quarter 2025 decreased 1% to $1.44 billion compared to $1.45 billion in the third quarter 2024.
• Net loss was $110 million in the third quarter 2025, an improvement from a net loss of $118 million in the third quarter 2024.
• Medical margin was negative $57 million during the third quarter 2025, compared to negative $58 million in the third quarter 2024.
• Adjusted EBITDA loss was $91 million in the third quarter 2025, an improvement from a loss of $96 million in the third quarter 2024.
• The third quarter 2025 results reflect a $73 million impact from lower-than-expected risk adjustment revenue, including a 9-month true-up for 28% of members.
• A $20 million negative impact from exited markets was also reflected in the third quarter 2025 results.
• Total members on the agilon platform decreased 6% year-over-year to 618,000 as of September 30, 2025, including 503,000 Medicare Advantage members and 115,000 ACO REACH model beneficiaries.
• Full-year 2025 guidance includes total revenues of $5.81 billion to $5.83 billion, medical margin of negative $5 million to positive $15 million, and Adjusted EBITDA loss of $270 million to $245 million.
• The full-year guidance reflects a $150 million impact from lower-than-expected risk adjustment revenue and approximately $70 million of negative prior period development year-to-date.
• The company expects $30 million in operating cost reductions in 2026.

Sentiment

Score: 4

Explanation: While management highlights progress on transformation initiatives and some year-over-year improvements in loss figures, the significant negative impact from risk adjustment revenue and exited markets, coupled with continued net losses and negative medical margins, indicates ongoing financial challenges. The re-established guidance reflects these headwinds, leading to a cautious outlook despite future cost reduction plans.

Positives

• Net loss improved to $110 million in Q3 2025 from $118 million in Q3 2024.
• Adjusted EBITDA loss improved to $91 million in Q3 2025 from $96 million in Q3 2024.
• Medical margin improved to negative $57 million in Q3 2025 from negative $58 million in Q3 2024.
• Expected $30 million in operating cost reductions for 2026.
• Enhanced data visibility, improved financial discipline in payor contracting processes, and reduced operating costs are being implemented.
• Strong ACO REACH performance demonstrates the Total Care Model's ability to deliver on shared savings, quality, and care experience.
• 75% of agilon members are in 4+ Star plans for PY27, with agilon-specific performance delivering 4.2 consolidated stars on average for PY27.
• The company maintains a strong balance sheet with $311 million in cash and short-term investments as of September 30, 2025 (excluding $172 million in ACO REACH entities cash).

Negatives

• Total revenue decreased 1% year-over-year in Q3 2025.
• Gross profit was negative $68 million in Q3 2025, compared to negative $64 million in Q3 2024.
• Lower-than-expected 2025 risk adjustment revenue of $73 million in Q3, including a 9-month true-up for 28% of members.
• A $20 million negative impact from exited markets was recorded in Q3 2025.
• Total members on the platform decreased 6% year-over-year to 618,000.
• Full-year 2025 guidance reflects a $150 million impact from lower-than-expected risk adjustment revenue.
• Medical margin guidance for full-year 2025 includes approximately $70 million of negative prior period development year-to-date and $60 million from exited markets.
• The company has a history of net losses and expects expenses to increase in the future.

Risks

• A history of net losses and the expectation that expenses will increase in the future.
• Failure to identify and develop successful new geographies, physician partners, and payors, or execute upon growth initiatives.
• Medical expenses incurred on behalf of members may exceed revenues received.
• Ability to maintain and secure additional contracts with Medicare Advantage payors on favorable terms, if at all.
• Ability to grow new physician partner relationships sufficient to recover startup costs.
• Availability of additional capital, on acceptable terms or at all, to support the business in the future.
• Significant reduction in membership.
• Transition to a Total Care Model may be challenging for physician partners.
• Inaccuracy in estimates of members' risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts.
• The impact of restrictive clauses or exclusivity provisions in some contracts with physician partners.
• Ability to hire and retain qualified personnel.
• Security breaches, cybersecurity attacks, loss of data, and other disruptions to information systems.
• Reliance on a limited number of key payors and the limited terms of contracts with payors and the ability to renew them upon expiration.
• The impact of changes to, and dependence on, federal government healthcare programs.
• Uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures.
• Regulation of the healthcare industry and the company's and its physician partners' ability to comply with such laws and regulations.
• Risks related to management transitions, including the search for a permanent CEO, and the ability to effectively manage leadership changes.

Future Outlook

The company re-established its full-year 2025 guidance, anticipating total revenues between $5.81 billion and $5.83 billion, medical margin between negative $5 million and positive $15 million, and an Adjusted EBITDA loss between $270 million and $245 million. For 2026, the company expects performance to be enhanced by positive CMS rates, favorable payer bids, improved contracting economics, and $30 million in operating cost reductions. However, changes to the ACO REACH program are expected to reduce year-over-year profitability.

Management Comments

• "In the third quarter we made tangible progress executing on our transformation initiatives while continuing to absorb the impact of historical challenges. We have enhanced data visibility, instilled a greater financial discipline in our payor contracting processes, and reduced operating costs." Ronald A. Williams, Executive Chair.
• "We are building a more streamlined, agile, accountable, and performance-driven organization. These efforts are already delivering measurable impact—reducing operating expenses by an expected $30 million in 2026, and supporting strong performance expectations for our BOI, clinical, and quality initiatives, with additional potential from more favorable rates, contract economics and payer bids." Ronald A. Williams, Executive Chair.
• "We remain focused on driving improved and sustainable financial performance in a dynamic healthcare market." Ronald A. Williams, Executive Chair.

Industry Context

The company operates in a dynamic healthcare market, focusing on accelerating the transition of physician groups and health systems to a value-based Total Care Model for senior patients. This aligns with broader industry trends towards value-based care, aiming to improve patient outcomes and reduce costs, moving away from traditional fee-for-service models. The emphasis on data visibility, financial discipline in contracting, and cost reductions reflects the competitive and evolving landscape of managed healthcare.

Stakeholder Impact

• Shareholders: Continued net losses and negative medical margins may impact share price and investor confidence. The re-established guidance reflects significant headwinds.
• Employees: Operating cost reductions and severance costs indicate potential impacts on the workforce.
• Physician Partners: The company's platform aims to empower physicians to transition to value-based care, but challenges in this model could affect partner relationships and financial outcomes.
• Payors: Enhanced financial discipline in payor contracting processes and negotiations for 2026 rates indicate ongoing engagement and potential changes in terms.

Next Steps

• Host a conference call on November 4, 2025, to discuss third-quarter 2025 results.
• Continue executing transformation initiatives to build a more streamlined, agile, accountable, and performance-driven organization.
• Focus on driving improved and sustainable financial performance in a dynamic healthcare market.
• Implement operating cost reductions of $30 million in 2026.
• Negotiate contracting for 2026 expectations, including improved economics, reduced Part D risk, and enhanced quality incentives.

Key Dates

Recommendation

The company continues to face significant financial headwinds, including substantial risk adjustment revenue impacts and ongoing net losses. While management is actively pursuing transformation initiatives and projecting future cost reductions and improved economics for 2026, the current financial performance remains challenging. The re-established guidance reflects these difficulties. A 'hold' recommendation is appropriate for investors to observe the effectiveness of the transformation efforts and the realization of anticipated 2026 improvements before making further investment decisions, given the inherent risks in a dynamic healthcare market.

Keywords

agilon health, AGL, Healthcare, Value-Based Care, Medicare Advantage, ACO REACH, Financial Results, Q3 2025, Risk Adjustment, Medical Margin, Adjusted EBITDA, Physician Partners, Operating Costs, Transformation Initiatives